Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by W. Aberer
S3-Leitlinie Atopische Dermatitis: Teil 2-Systemische Therapie
S3-Leitlinie Atopische Dermatitis: Teil 2-Systemische Therapie Research output: Contribution to journal › Research article › Contributed › peer-review
Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German‐speaking countries
ORIGINAL ARTICLE V. Wahn Corresponding Author E-mail address: Volker.Wahn@charite.de Department of Pediatric Pneumology, Immunology, and Intensive Care Medicine, Charité Universitätsmedizin, Berlin, Germany All authors contributed equally to this work. Corresponding author: Prof.
Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy
Abstract Background The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX® Quattro Plus 1.0 ml Birch 100%) is an effective, well‐tolerated short course subcutaneous immunotherapy. We performed 2 phase II studies to determine its optimal cumulative dose. Methods The studies were conducted in Germany, Austria and Poland (EudraCT numbers: 2012‐004336‐28 PQBirch203 and 2015‐000984‐15 PQBirch204) using a wide range of cumulative doses.
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Abstract This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016.
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
Abstract This guideline is the result of a systematic literature review using the ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin.
Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
Research | Open | Published: 19 July 2019 Anette Bygum ORCID: orcid.org/0000-0002-3004-01801,2, Teresa Caballero3, Anete S. Grumach4, Hilary J.
Corrigendum - - 2018 - Allergy - Wiley Online Library
Forgot your password? Enter your email address below. If your address has been previously registered, you will receive an email with instructions on how to reset your password. If you don't receive an email, you should register as a new user Please check your email for your password reset instructions.
Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy
The Birch Allergoid, Tyrosine Adsorbate, Monophosphoryl Lipid A (POLLINEX® Quattro Plus 1.0 ml Birch 100%) is an effective, well‐tolerated short course subcutaneous immunotherapy. We performed 2 phase II studies to determine its optimal cumulative dose. The studies were conducted in Germany, Austria and Poland (EudraCT numbers: 2012‐004336‐28 PQBirch203 and 2015‐000984‐15 PQBirch204) using a wide range of cumulative doses.
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016.
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
This evidence‐ and consensus‐based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016.
P164 Longitudinal natural history of patients with type I/II hereditary angioedema: icatibant outcome survey data
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. The natural course of hereditary angioedema due to C1-inhibitor deficiency (C1 INH-HAE) is not well understood. The Icatibant Outcome Survey (IOS) is an international observational study that monitors the safety and effectiveness of icatibant in a real-world setting.
Dermatitis, nonmelanoma skin cancer and leg ulcers
CPD ? Clinicopathological caseDermatitis, nonmelanoma skin cancer and leg ulcersAuthorsL. Koch,Department of Dermatology, Medical University of Graz, Graz, AustriaSearch for more papers by this authorR. Lichem,Department of Dermatology, Medical University of Graz, Graz, AustriaSearch for more papers by this authorL. Cerroni,Department of Dermatology, Medical University of Graz, Graz, AustriaSearch for more papers by this authorW.
A position paper on drug allergy - pinpointing problems rather than suggesting solutions
EditorialYou have free access to this contentA position paper on drug allergy – pinpointing problems rather than suggesting solutionsW. AbererVersion of Record online: 8 JUL 2016DOI: 10.1111/all.12910© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with W.
Contact W., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack